LAM Therapeutics launches operations to develop drugs for rare lung disease, Lymphangioleiomyomatosis (LAM)

Return to News >

Company is first to focus on developing drugs for Lymphangioleiomyomatosis

Guilford, CT – June 6, 2013 – LAM Therapeutics, the first biopharmaceutical company dedicated to identifying and developing drugs for the treatment of Lymphangioleiomyomatosis (LAM), announced today that it has closed a Series A financing with private investors to launch operations. Proceeds […]

2017-12-20T10:56:35+00:00 June 6th, 2013|Categories: News|